Schiffelers, Lisa D. J. https://orcid.org/0000-0003-2301-1610
Tesfamariam, Yonas M. https://orcid.org/0000-0003-0106-7277
Jenster, Lea-Marie
Diehl, Stefan https://orcid.org/0000-0002-8058-7897
Binder, Sophie C. https://orcid.org/0009-0004-5573-1131
Normann, Sabine
Mayr, Jonathan https://orcid.org/0009-0008-8241-4720
Pritzl, Steffen
Hagelauer, Elena https://orcid.org/0009-0002-4004-1846
Kopp, Anja https://orcid.org/0000-0001-5484-7109
Alon, Assaf https://orcid.org/0000-0001-8102-5290
Geyer, Matthias https://orcid.org/0000-0002-7718-5002
Ploegh, Hidde L. https://orcid.org/0000-0002-1090-6071
Schmidt, Florian I. https://orcid.org/0000-0002-9979-9769
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (SFB1403- 414786233)
Deutsche Forschungsgemeinschaft (Germany’s Excellence Strategy – EXC2151–390873048)
Deutsche Forschungsgemeinschaft (GRK2168-272482170)
Article History
Received: 12 March 2024
Accepted: 27 August 2024
First Online: 26 September 2024
Competing interests
: FIS is cofounder and shareholder of Odyssey Therapeutics. LDJS, SN, AK, MG, HLP, and FIS are listed as inventors of a pending patent application on GSDMD nanobodies. The remaining authors declare no competing interests.